20-02-23 Q. What's in the Contraceptive Pipeline for Women

23rd Annual Premier Women's Healthcare Virtual Conference

1.25 CE, 1.25 Rx (NCC 4)

Anyone who was registered for the Main Conference, Oct 16-17, 2020, will have access to all recordings, free of any additional charge, for 12 months. 

Please note:  Those who did not register for the conference will be able to purchase session recordings starting March 1, 2020. 

Faculty:

Anita Nelson MD

Professor and Chair OB-GYN

Western University of Health Sciences

Pomona, California  

Intended Audience:

Women’s Health Nurse Practitioners (WHNPs), WHNP students, Certified Nurse Midwives (CNMs) and other nurse practitioners and advanced practice clinicians who care for women.

 Activity Number:  20-02-23

 CE Approval Period:  Now through November 15, 2021

 Approved CE Credit Hours:  1.25 CE contact hour credits, 1.25 hours pharmacology.

 Accreditation Statement:

This activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health for 1.25 CE contact hours, 1.25 hours of pharmacology content. 

 Program Description:

There have been many new contraceptive methods introduced in the last several years, but the unintended pregnancy rate remains high. This certainly reflects women’s ambivalence and indifference to controlling their fertility but may also reflect the need for more options. This talk will review what is in the pipeline now.

 Educational Objectives:

At the conclusion of this activity, the learner will be able to:

  • List the new developments in long acting reversible methods.
  • Describe the new combined hormonal and barrier methods under development.
  • Explain barriers to reducing unintended pregnancy.

Faculty Disclosures:

Anita Nelson MD has the following disclosures:  Speakers bureau for American Regent, Bayer Healthcare, Merck and Theraputics MD; Consultant/Independent Contractor for Agile Pharmaceuticals, AMAG, American Regent, Bayer Healthcare, Merck, Sebela Pharmaceutical, Theraputics MD and Contracted Research with Agile Pharmaceutical EvoFem, Merck, Mithra and Sebela Pharmaceutical.

 Successful Completion:

Successful completion of this activity requires the participant to:

  1. Read the educational objectives, disclosures and disclaimers.
  2. Watch the session recording
  3. Complete the session evaluation
  4. Print your CE certificate (the certificate will be stored on the NPWH E-Learning site under My Transcripts).
  5. These steps must be completed prior to the course expiration date
  6. Some courses required a post-test.  If a post test is required participants must earn a score of 70%.   

Therapeutic Disclosures:

Faculty members determine the content of the CE activity.  The content does not necessarily represent the views of NPWH.  Clinicians are responsible for evaluating information presented in relation to generally accepted standards of care and individual patient characteristics.

 Commercial Support: 

This activity has no commercial support

You must be signed in to access this course.  You can sign in at the top right-hand corner of the page.

 **If you are an NPWH member, were once a member, or have completed CE activities with NPWH in the past, you have a username and password in the system.  Please DO NOT create a new account.  If you do not remember your username or password, please either click on the “forgot username” or “forgot password” link at the bottom of the sign on screen or call the NPWH office at (202) 543-9693 ext. 81

Pricing

Non-Member/Inactive Member Student Member
$30.00 $15.00 $15.00
20-02-23 Q. What's  in the Contraceptive Pipeline for Women